Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-05), Wakamoto Pharmaceutical Co's 3-1 Month Momentum % is 1.13%.
The industry rank for Wakamoto Pharmaceutical Co's 3-1 Month Momentum % or its related term are showing as below:
TSE:4512's 3-1 Month Momentum % is ranked better than 58.51% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -1.16
vs TSE:4512: 1.13
Wakamoto Pharmaceutical Co (TSE:4512) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Wakamoto Pharmaceutical Co 3-1 Month Momentum % Related Terms
TSE:4512 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's 3-1 Month Momentum % falls into.
Wakamoto Pharmaceutical Co (TSE:4512) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a 3-1 Month Momentum % of 1.13% as of Sep. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wakamoto Pharmaceutical Co and its competitors. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #424 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is Wakamoto Pharmaceutical Co's 3-1 Month Momentum % too high?
Wakamoto Pharmaceutical Co's current 3-1 Month Momentum % is 1.13%. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #424 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #424 out of 1022 companies for 3-1 Month Momentum %. This puts Wakamoto Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current 3-1 Month Momentum % is 1.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円310.12, compared to a current price of 円306.00 — trading 1.3% below its estimated fair value. The current 3-1 Month Momentum % is 1.13%. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current 3-1 Month Momentum % is 1.13% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円306.00 is trading 1.3% below its estimated GF Value™ of 円310.12.
GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4512:
3-1 Month Momentum %: 1.13%
GF Value™: 円310.12 vs. price of 円306.00 (1.3% below fair value)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
